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Various destabilizing factors of the ubiquitin system
contribute to the synchrony and unidirectionality of
the cell cycle clock by finely tuning the activity of var-
ious CDKs. The recent findings of hierarchical and
connected waves of cyclin stabilizers highlight the
complexity of this network.
How to Keep CDK Activity Low in G0
and High in ‘‘C Phase’’
The cell relies on three major systems to maintain the
quiescent state (or G0 phase): the pocket proteins
(pRb, p107, and p130), Cdh1, and certain CDK inhibitors
(CKIs) (Figure 1A). Critical downstream targets of the
three G0 guardians are Cdk1 and Cdk2, two kinases
that lie at the very core of the cell cycle machinery and
constitute its major driving force (Murray, 2004). Pocket
proteins repress the activity of the members of the E2F
transcription factor family (particularly E2F1-3), which
induce the transcription of many positive cell cycle reg-
ulators, including CDK activators such as cyclins (type
A, B, and E) and Cdc25 protein phosphatases (Yamasaki
and Pagano, 2004). Cdh1 activates the anaphase pro-
moting complex/cyclosome (APC/C) ubiquitin ligase to
promote the degradation of a number of positive regula-
tors of S phase and mitosis (Ang and Harper, 2004; Pe-
ters, 2002). These include cyclins (type A and B) and
Cdc25A. A further activator of Cdk1 and Cdk2, Skp2, is
also a target of APC/CCdh1 (Kurland and Tansey, 2004).
Skp2 is an F box protein and constitutes the substrate
recognition subunit of an SCF (Skp1/Cul1/F box protein)
ubiquitin ligase complex (Cardozo and Pagano, 2004)
that targets the CKIs p21 and p27 for degradation. Deg-
radation of Skp2 by APC/CCdh1 contributes to increase
the levels of these CKIs in quiescent cells.
Quiescence is self-sustaining; however, mitogenic
stimuli are able to induce G0 cells to enter the cell cycle.
To do so, mitogens need to inhibit each of the G0 regu-
lators: pocket proteins, Cdh1, and CKIs. This inhibition
is the product of complex signaling pathways that start
at the membrane and eventually lead to the activation of
Cdk1 and Cdk2 (Figure 1B). These two kinases will then
remain active from late G1 until anaphase. We propose
to define this interval of time ‘‘C phase,’’ a phase with ac-
tive Cdk1/Cdk2, as opposed to G0, early G1, and telo-
phase that are characterized by no Cdk1/Cdk2 activity.
Significantly, the start of the cell cycle requires CDKs
to act upstream of pocket proteins, Cdh1, and CKIs, re-
versing the inhibition of CDKs exerted by these factors in
G0 (Figure 1B). The gradual phosphorylation of each of
*Correspondence: michele.pagano@med.nyu.eduthese inhibitors by Cdk1 and Cdk2 (and other CDKs, at
least in the case of pocket proteins) induces their inacti-
vation. Phosphorylation of pocket proteins induces their
dissociation from E2F transcription factors, thereby al-
lowing their activation. Phosphorylation of Cdh1 leads
to its dissociation from APC/C, resulting in the inactiva-
tion of this ubiquitin ligase. Finally, phosphorylation of
p21 and p27 promotes their degradation through
SCFSkp2. All this creates autoamplification loops that
render Cdk1 and Cdk2 increasingly more active.
An important consequence of E2F activation is the
transcription of Emi1, a central inhibitor of APC/C (Hsu
et al., 2002). In addition, APC/C contributes to its own in-
activation by mediating the degradation of both its acti-
vator Cdh1 and its ubiquitin conjugating enzyme, Ubc10
(Lukas and Bartek, 2004). Thus, at least three signals co-
operate to keep APC/CCdh1 inactive from G1/S until late
mitosis: CDKs, Emi1, and APC/CCdh1 itself. This intricate
mechanism clearly highlights the need for the cell to in-
hibit APC/CCdh1 during a time in which CDKs need to be
active.
How to Keep Cdk1 Activity Low in S-G2
and High at G2/M
Cdk1 activity accumulates slowly during S and G2 and
reaches maximal activation only in mitosis, whereas
Cdk2 reaches its peak of activity earlier in S phase.
The sum of Cdk1 and Cdk2 activities during S and G2
is much lower than the activity of Cdk1 in early mitosis
alone (Bashir and Pagano, 2005). Low CDK activity is
permissive for DNA replication, whereas the inhibition
of DNA rereplication and entry into mitosis require
higher thresholds. Thus, the attenuation of Cdk1 activity
prevents entry into mitosis prior to the completion of
DNA synthesis and the verification of its fidelity. The in-
hibitory phosphorylation of Cdk1 on its ATP binding site
by the kinase Wee1 is responsible for restraining Cdk1
activity during S and G2 phase. To avoid the action of
Wee1 being neutralized, the phosphatase Cdc25A
needs to be kept at bay. This is achieved by bTrcp-
mediated degradation of Cdc25A triggered through
Cdc25A phosphorylation by the DNA replication check-
point kinase Chk1. At G2/M, full activation of Cdk1 is
allowed by turning the checkpoint off, leading to the
consequent inactivation of Chk1 and accumulation of
Cdc25A. At the same time, Cdk1 (in conjunction with
Plk1) furthermore phosphorylates Wee1, creating a
phospho-degron for the recognition by bTrcp. Thus,
SCFbTrcp attenuates Cdk1 activity during S and G2 (by
inducing Cdc25A degradation) but contributes to its
full activation at G2/M (by promoting the proteolysis of
Wee1).
How the Circle Closes
CDKs not only phosphorylate downstream substrates to
generate autoamplification loops (as is the case for
pocket proteins, Cdh1, p21, p27, and Wee1), but they
also generate negative feedback signals that will induce
their own inactivation in late M. For example, in G2, Cdk1
and Cdk2—in association with cyclin A—phosphorylate
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2Figure 1. The G0 State Is Self-Sustaining,
whereas the C Phase Contains the Program
for Its Own Shutdown
(A) In the absence of mitogenic stimuli, pRb
and other pocket proteins, Cdh1, and certain
CKIs are responsible for maintaining the qui-
escent state or G0. This is achieved, at least
in part, by preventing the activation of CDKs.
(B) In response to mitogenic signals, CDKs
become active and subsequently phosphory-
late and inactivate pocket proteins, Cdh1, and
CKIs. This generates positive autoamplifica-
tion loops that render CDKs increasingly
more active as the cell progresses from
G1/S to mitosis. However, the C phase (or
phase of CDK activity) is programmed to
end in late mitosis. For example, Cdk1 pro-
motes the activation of APC/CCdc20, both by
phosphorylating certain subunits of APC/C
and by inducing the degradation of Emi1
(see Figure 2). In turn, active APC/CCdc20
causes the degradation of cyclins with the
consequent inactivation of Cdk1. At the end
of the cell cycle, Cdc14 and other phospha-
tases (PPs) dephosphorylate many of the
substrates phosphorylated by CDKs during
the C phase. Please note that the amplitude
of the curves representing each phase is not
in scale with the actual time length. For exam-
ple, the C phase is much longer than the inter-
val between late mitosis and the next G1.E2F1 and E2F3, resulting in the inactivation of these two
transcription factors (Yamasaki and Pagano, 2004). In
prometaphase, phosphorylation of Emi1 by Cdk1 and
subsequently by Plk1 induces the bTrcp-dependent
degradation of this APC/C inhibitor (Guardavaccaro
et al., 2003; Margottin-Goguet et al., 2003). This event
triggers the activation of a different form of APC/C,
namely APC/CCdc20 (Figure 1B). Cdk1 further contrib-
utes to the activation of APC/CCdc20 by phosphorylating
some of its subunits. However, only when all chromo-
somes have completed bipolar attachment to the mi-
totic spindle does the APC/CCdc20 ubiquitin ligase reach
full activity and allow the metaphase-anaphase transi-
tion to occur by inducing the degradation of securins
and thus promoting the separation of the sister chroma-
tids (Reed, 2003). Significantly, the same ubiquitin ligase
responsible for the segregation of the chromosomes
destined to the two daughter cells also induces the deg-
radation of A and B type cyclins, thereby inhibiting Cdk1
activity and resetting the cell cycle to low CDK activity
for the ‘‘newborn/G1’’ cells.
What occurs at the exit from mitosis is better under-
stood in yeast than in higher eukaryotes, although the
general mechanisms seem to be conserved. It appears
that at the end of the long-lasting reign of CDKs there
is a short time in which phosphatases (Cdc14 and likely
others such as PP2A and PP1) rule to revert the effects
of CDKs by dephosphorylating substrates previously
targeted by CDKs (Figure 1B), among them pocket pro-teins (resulting in the inhibition of E2F1-3) and Cdh1
(Bosl and Li, 2005). Cdh1 in its unphosphorylated state
is free to bind to APC/C and keep it active from late mi-
tosis to late G1. In turn, APC/CCdh1 induces the degrada-
tion of Skp2, giving rise to upregulation of p21 and p27.
The circle is finally closed, and the cell cycle clock is re-
set: the two daughter cells generated by one cell division
cycle are back in G1 and will proceed into S only if favor-
able conditions are still present. If not, pocket proteins,
Cdh1, and CKIs will again cooperate in maintaining the
G1 state and eventually in promoting entry into quies-
cence. Significantly, the keepers of the G0 state have
also been implicated in cell differentiation, and most of
them are also expressed in postmitotic cells. Thus,
they also appear to be inducers and guardians of the dif-
ferentiated state.
In summary, the cell cycle is characterized by
a buildup of CDK activity, and many negative feedbacks
emanating from CDKs themselves ensure that at the end
of one cycle CDK activity is downregulated to allow exit
from mitosis. In fact, unless cyclins are ubiquitylated by
APC/C, an intramitotic checkpoint prevents departure
from anaphase (Murray, 2004). Clearly, the ubiquitin sys-
tem strongly contributes to the synchrony and unidirec-
tionality of the cell cycle by ensuring that various cell cy-
cle gates are opened at the right time. A variety of CDKs
and cyclins (combined with their differential transcrip-
tion, translation, degradation, subcellular localization,
and posttranslational modifications) have evolved to
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3Figure 2. The Evi5-Emi1-APC/C Axis as an Example of Stabilizers and Destabilizers Controlling Both Positively and Negatively CDK Activity
Black color signifies activated forms of the respective proteins, and turquoise indicates inactive forms or degraded proteins.
(A) New results suggest that during most of the C phase, Evi5 prevents Emi1 phosphorylation by Plk1 and its consequent recruitment by
SCFbTrcp. Emi1 is thus protected from degradation and, by blocking the activity of APC/C, drives the accumulation of cyclin A, which contributes
to the activation of Cdk1 and Cdk2. The asterisk indicates that the E2F-mediated transcriptional activation of cyclin A is not present during G2. In
fact, during this phase, cyclin A induces the phosphorylation and inactivation of certain E2F family members.
(B) In prometaphase, Plk1 phosphorylates Evi5, triggering its destruction. Unbound Emi1 is in turn phosphorylated by Cdk1 and Plk1, ubiquity-
lated by SCFbTrcp, and degraded by the proteasome. APC/C becomes active and induces both the entry into anaphase and the degradation of
mitotic cyclins, thereby inactivating Cdk1.provide a complex control system for the cell cycle ma-
chinery. Focusing on the proteolytic mechanisms only,
the following scenario appears: in early G1, CDKs are
kept in check by APC/CCdh1, during the C phase, CDK
activity is stimulated by SCFSkp2, and in late mitosis, it
is inhibited by APC/CCdc20. This system appears to in-
duce a binary response: OFF, ON, and back to OFF.
However, another ubiquitin ligase, SCFbTrcp, provides
exquisitely fine regulation of Cdk1 activity thresholds
by controlling Cdc25A, Wee1, and Emi1 during different
phases of the cell cycle.
How to Stabilize Cyclin A: Emi1 and Evi5
A recent study (Eldridge et al., 2006) has introduced
a new player controlling the oscillation of cell cycle regu-
latory proteins. This protein is called Evi5 and its activity
is to inhibit the degradation of Emi1 (Figure 2A). Earlier
work demonstrated that, in addition to destabilizing
factors (i.e., most ubiquitin conjugating enzymes and
ubiquitin ligases), the ubiquitin system also includes sta-
bilizers. These consist of certain deubiquitylating en-
zymes (e.g., Usp7), inhibitors of ubiquitin ligases (e.g.,
Emi1 and Mad proteins), certain kinases (e.g., CDKs
phosphorylating Cdh1), inhibitors of kinases (e.g., inhib-
itors of GSK3b in the WNT pathway), etc. Evi5, however,
works by a novel mechanism. It associates with Emi1
and protects it from SCFbTrcp ubiquitylating activity.
Specifically, Evi5 binds directly to a region of Emi1
surrounding the degron that is phosphorylated by
Plk1. As a result, it prevents the phosphorylation and
the subsequent recruitment by SCFbTrcp. It is believed
that the timing of association between substrates andSCF ligases is dictated by either the availability of the
F box protein (e.g., inverse correlation of Skp2 with
p27 levels) or the kinase that phosphorylates the sub-
strate (e.g., inverse correlation of Chk1 activity with
Cdc25A levels) (Petroski and Deshaies, 2005). Thus,
the new finding has profound implication, as Evi5 pro-
vides additional means of control by blocking the phos-
phorylation of the SCF substrate.
Importantly, Evi5 levels themselves oscillate during
the cell cycle, being high from early G1 to the beginning
of mitosis. The mitotic decrease in Evi5 levels is once
again due to the activity of Plk1, which phosphorylates
a C-terminal degron and thus triggers Evi5 destruction
by an as yet unknown ubiquitin ligase. In late mitosis,
the destruction of Plk1 allows the restabilization and re-
accumulation of Evi5.
Thus, the C phase is characterized by an ensemble
of three hierarchical and largely concomitant waves of
stability: Evi5 stabilization leads to Emi1 accumulation,
which in turn causes the stabilization of cyclin A
(Figure 2A). Later, in early mitosis, Plk1 phosphorylates
Evi5, promoting its degradation. As a result, Emi1 also
becomes accessible to Plk1-mediated phosphorylation
and is consequently eliminated via SCFbTrcp. This event,
together with the phosphorylation of specific APC/C
subunits by Cdk1, leads to the full activation of APC/
CCdc20 and the consequent degradation of mitotic cy-
clins (Figure 2B). At the end of the C phase, Plk1 is de-
graded via APC/CCdh1, permitting the accumulation of
Evi5 and the rebuilding of a protective shield for the
newly synthesized Emi1 during the next G1/S. However,
because Plk1 is only active in G2 and mitosis, the
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shield Emi1 from phosphorylation by other members of
the polo-like kinase family. Alternatively, Evi5 would pro-
tect Emi1 from low Plk1 activity and from premature Plk1
activation.
Although the function of Evi5 in establishing a defined
period of Emi1 stability during the C phase is mostly
understood, it is still unclear where in the cell all this takes
place. Evi5 is a protein localized mostly to the centro-
some (Eldridge et al., 2006; Faitar et al., 2005), and poten-
tially important subpopulations of most of the other
players (bTrcp, Skp1, Cul1, cyclins, Plk1, Plk2, and
Emi1) localize to the centrosome as well. One possibility
is that Evi5 promotes the stabilization of the centrosomal
pool of Emi1 only, causing cyclin A accumulation on the
centrosome. This might explain how Evi5 stabilizes a
centrosomal pool of cyclin A, a protein that is required
for centrosomal duplication during S phase. However,
this scenario does not clarify why the downregulation
of Evi5 leads to the disappearance of the total cellular
pools of Emi1 and cyclin A. It is possible that Emi1 is
only ubiquitylated and degraded on the centrosome
and thus generates a ‘‘draining force,’’ which siphons
off the entire pool of Emi1 and cyclin A. According to
this model, Evi5 would act as a plug to stop the degrada-
tion of cyclin A and therefore provide a direct link be-
tween the centrosome cycle and the cell division cycle.
There are additional unclear issues. How is Evi5 ex-
pression induced in G1? And what is the nature of the
ubiquitin ligase that triggers Evi5 destruction in early mi-
tosis? Evi5 appears in G1 a few hours before Emi1. Do
other proteins exist that are stabilized by Evi5 during
this window of time? All these unanswered questions
are of particular importance given the role of Evi5 in
the regulation of APC/C activity.
The Evi5-Emi1-APC/C Axis and Cancer
It is worth mentioning that the G0 keepers are either tu-
mor suppressors or at least display some cancer sup-
pressor characteristics (Sherr, 2004). In contrast, many
positive regulators of cell cycle progression are proon-
cogenic (e.g., A and E type cyclins, Cdc25A, E2F3,
Emi1, and Skp2) (Sherr, 1996; Yamasaki and Pagano,
2004). Evi5 may belong to the latter group. Indeed,
Evi5 was originally isolated as a product of a gene fre-
quently targeted by retroviral integration in murine
T cell lymphomas (Liao et al., 1997). In another study, it
was found truncated as the result of a chromosomal
translocation in a patient with stage 4S neuroblastoma
(Roberts et al., 1998). It is still uncertain if these genomic
alterations suppress Evi5 expression or generate a trun-
cated version with modified biological activity. In spite
of this, the fact that Evi5 is a target of genomic rear-
rangements suggests a role for Evi5 in oncogenesis.
Evi5 may favor tumorigenesis by its ability to stabilize
Emi1. Experiments in cultured cells have shown that de-
regulation of Emi1 proteolysis during prometaphase
causes mitotic aberrations such as misalignment of
the chromosomes and abnormal spindle formation
(Guardavaccaro et al., 2003; Margottin-Goguet et al.,
2003), which may potentially be a cause of aneuploidy
in daughter cells able to escape mitotic catastrophe. In
addition to aneuploidy, these daughter cells would
have a G1 phase characterized by high levels of Emi1with consequent inhibition of APC/CCdh1 and accumula-
tion of positive regulators of the cell cycle. This, in turn,
would lead to premature entry into S phase, a further
cause of genomic instability (Murray, 2004). Theoreti-
cally, this scenario could be mimicked by deregulated
expression of Evi5. Additional studies will be needed
to fully understand the importance of the Evi5-Emi1-
APC/C axis in oncogenesis.
Outlook
Despite the large body of work on the cell cycle and the
ubiquitin system, we are only scraping at the surface of
a more complex network. The findings on Emi1 and Evi5
may potentially implicate that additional proteins with
similar stabilizing functions control the cell cycle and
other cellular processes. Moreover, hundreds of differ-
ent ubiquitin ligases and isopeptidases exist in mamma-
lian cells, which begs the question of how many of them
play a role in cell cycle control. How are all these en-
zymes regulated and how do they functionally interact
with each other? Is phosphorylation the only language
understood by cell cycle ubiquitin ligases or can addi-
tional posttranslational modifications impinge on their
activity and/or recognition of substrates? Finally, what
are the variations on the theme in different cell types in
the various tissues? These are only some of the areas
that will likely experience intense research activities in
the near future.
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